Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations

Brain

Volumn 138, Issue 9, 2015, Pages 2648-2658

  Alcalay, Roy N ^a   Levy, Oren A ^a   Waters, Cheryl C ^a   Fahn, Stanley ^a   Ford, Blair ^a   Kuo, Sheng Han ^a   Mazzoni, Pietro ^a   Pauciulo, Michael W ^b   Nichols, William C ^b   Gan Or, Ziv ^c   Rouleau, Guy A ^c   Chung, Wendy K ^a   Wolf, Pavlina ^d   Oliva, Petra ^d   Keutzer, Joan ^d   Marder, Karen ^a,e   Zhang, Xiaokui ^d  

^a Columbia University Medical Center ^*  (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d SANOFI   (France)

^e Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

Author keywords

genetics; glucocerebrosidase; LRRK2; lysosome; Parkinson's disease

Indexed keywords

GLUCOSYLCERAMIDASE; LEUCINE RICH REPEAT KINASE 2; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRIED BLOOD SPOT TESTING; ENZYME ACTIVITY; FEMALE; GAUCHER DISEASE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; UNITED STATES; COHORT ANALYSIS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; JEW; METABOLISM; MIDDLE AGED; MUTATION; SEVERITY OF ILLNESS INDEX;

AGED; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOTYPE; GLUCOSYLCERAMIDASE; HUMANS; JEWS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SEVERITY OF ILLNESS INDEX;

EID: 84940770418     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv179     Document Type: Article

References (49)

1. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004; 351: 1972-7. doi: 351/19/1972 [pii] 10. 1056/ NEJMoa033277
2. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang M, Rosado L, Orbe Reilly M, et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 2012; 78: 1434-40. doi: 10. 1212/WNL. 0b013e318253d54b
3. Alcalay RN, Dinur T, Quinn T, Sakanaka K, Levy O, Waters C, et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol 2014; 71: 752-7. doi: 10. 1001/jamaneurol. 2014. 313
4. Alcalay RN, Mirelman A, Saunders-Pullman R, Tang MX, Mejia Santana H, Raymond D, et al. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord 2013; 28: 1966-71. doi: 10. 1002/mds. 25647
5. Balducci C, Pierguidi L, Persichetti E, Parnetti L, Sbaragli M, Tassi C, et al. Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. Mov Disord 2007; 22: 1481-4. doi: 10. 1002/ mds. 21399
6. Bras J, Paisan-Ruiz C, Guerreiro R, Ribeiro MH, Morgadinho A, Januario C, et al. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiol Aging 2009; 30: 1515-17. doi: S0197-4580(07)00447-2 [pii] 10. 1016/j.neurobiolaging. 2007. 11. 016
7. Clark LN, Kartsaklis LA, Wolf Gilbert R, Dorado B, Ross BM, Kisselev S, et al. Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch Neurol 2009; 66: 578-83. doi: 66/ 5/578 [pii] 10. 1001/archneurol. 2009. 54
8. Clark LN, Ross BM, Wang Y, Mejia-Santana H, Harris J, Louis ED, et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 2007; 69: 1270-7. doi: 69/ 12/1270 [pii] 10. 1212/01. wnl. 0000276989. 17578. 02
9. Cullen V, Sardi SP, Ng J, Xu YH, Sun Y, Tomlinson JJ, et al. Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing. Ann Neurol 2011; 69: 940-53. doi: 10. 1002/ana. 22400
10. Duran R, Mencacci NE, Angeli AV, Shoai M, Deas E, Houlden H, et al. The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Mov Disord 2013; 28: 232-6. doi: 10. 1002/mds. 25248
11. Fahn S, Elton R; Members of the UPDRS Development Committee. The unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson's disease. Vol. 2. Florham Park, NJ: Macmillan Healthcare Information; 1987.
12. Gan-Or Z, Giladi N, Rozovski U, Shifrin C, Rosner S, Gurevich T, et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 2008; 70: 2277-83. doi: 01. wnl. 0000304039. 11891. 29 [pii] 10. 1212/ 01. wnl. 0000304039. 11891. 29
13. Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 2012; 72: 455-63. doi: 10. 1002/ana. 23614
14. Giraldo P, Capablo JL, Alfonso P, Garcia-Rodriguez B, Latre P, Irun P, et al. Neurological manifestations in patients with Gaucher disease and their relatives, it is just a coincidence? J Inherit Metab Dis 2011; 34: 781-7. doi: 10. 1007/s10545-011-9298-4
15. Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 2008; 65: 1353-7. doi: 65/10/1353 [pii] 10. 1001/archneur. 65. 10. 1353
16. Grabowski GA, Dinur T, Gatt S, Desnick RJ. Gaucher type-1 (Ashkenazi) disease-a new method for heterozygote detection using a novel fluorescent natural substrate. Clin Chim Acta 1982; 124: 123-35. doi: Doi 10. 1016/0009-8981(82)90326-6
17. Halperin A, Elstein D, Zimran A. Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol Dis 2006; 36: 426-8. doi: S1079-9796(06)00081-7 [pii] 10. 1016/j. bcmd. 2006. 02. 004
18. Horowitz M, Pasmanik-Chor M, Borochowitz Z, Falik-Zaccai T, Heldmann K, Carmi R, et al. Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population (vol 12, pg 240, 1998). Hum Mutat 1999; 13: 255-5.
19. Horowitz M, Pasmanik-Chor M, Ron I, Kolodny EH. The enigma of the E326K mutation in acid beta-glucocerebrosidase. Mol Genet Metab 2011; 104: 35-8. doi: 10. 1016/j. ymgme. 2011. 07. 002
20. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
21. Kalinderi K, Bostantjopoulou S, Paisan-Ruiz C, Katsarou Z, Hardy J, Fidani L. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neurosci Lett 2009; 452: 87-9. doi: S0304-3940(09)00059-7 [pii] 10. 1016/ j. neulet. 2009. 01. 029
22. Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E. Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 2004; 81: 70-3. doi: S1096719203002646 [pii]
23. MacLeod DA, Rhinn H, Kuwahara T, Zolin A, Di Paolo G, McCabe BD, et al. RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 2013; 77: 425-39. doi: 10. 1016/j. neuron. 2012. 11. 033
24. Marder K, Levy G, Louis ED, Mejia-Santana H, Cote L, Andrews H, et al. Accuracy of family history data on Parkinson's disease. Neurology 2003; 61: 18-23.
25. Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011; 146: 37-52. doi: 10. 1016/j. cell. 2011. 06. 001
26. McNeill A, Magalhaes J, Shen C, Chau KY, Hughes D, Mehta A, et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 2014; 137(Pt 5): 1481-95. doi: 10. 1093/brain/awu020
27. Mitsui J, Mizuta I, Toyoda A, Ashida R, Takahashi Y, Goto J, et al. Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol 2009; 66: 571-6. doi: 66/5/571 [pii] 10. 1001/archneurol. 2009. 72
28. Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E, et al. Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. Brain 2014; 137: 834-48. doi: Doi 10. 1093/Brain/Awt367
29. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695-9. doi: 10. 1111/j. 1532-5415. 2005. 53221. x
30. Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, Aghai E, et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 1996; 89: 691-4.
31. Neumann J, Bras J, Deas E, O'Sullivan SS, Parkkinen L, Lachmann RH, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009; 132(Pt 7): 1783-94. doi: Awp044 [pii] 10. 1093/brain/awp044
32. Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 2009; 72: 310-16. doi: 10. 1212/01. wnl. 0000327823. 81237. d1
33. Olivova P, Cullen E, Titlow M, Kallwass H, Barranger J, Zhang K, et al. An improved high-throughput dried blood spot screening method for Gaucher disease. Clin Chim Acta 2008; 398: 163-4. doi: S0009-8981(08)00431-2 [pii] 10. 1016/j. cca. 2008. 08. 024
34. Orenstein SJ, Kuo SH, Tasset I, Arias E, Koga H, Fernandez-Carasa I, et al. Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci 2013; 16: 394-406. doi: 10. 1038/nn. 3350
35. Parnetti L, Balducci C, Pierguidi L, De Carlo C, Peducci M, D'Amore C, et al. Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies. Neurobiol Dis 2009; 34: 484-6. doi: DOI 10. 1016/j. nbd. 2009. 03. 002
36. Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, Qureshi MM, et al. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Mov Disord 2014; 29: 1019-27. doi: 10. 1002/mds. 25772
37. Raghavan SS, Topol J, Kolodny EH. Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease. Am J Hum Genet 1980; 32: 158-73.
38. Reuser AJ, Verheijen FW, Bali D, van Diggelen OP, Germain DP, Hwu WL, et al. The use of dried blood spot samples in the diagnosis of lysosomal storage disorders-current status and perspectives. Mol Genet Metab 2011; 104: 144-8. doi: 10. 1016/ j. ymgme. 2011. 07. 014
39. Rosenbloom B, Balwani M, Bronstein JM, Kolodny E, Sathe S, Gwosdow AR, et al. The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. Blood Cells Mol Dis 2011; 46: 95-102. doi: 10. 1016/ j. bcmd. 2010. 10. 006
40. Sakanaka K, Waters CH, Levy OA, Louis ED, Chung WK, Marder KS, et al. Knowledge of and interest in genetic results among parkinson disease patients and caregivers. J Genet Couns 2014; 23: 114-20. doi: 10. 1007/s10897-013-9618-y
41. Salvioli R, Tatti M, Ciaffoni F, Vaccaro AM. Further studies on the reconstitution of glucosylceramidase activity by Sap C and anionic phospholipids. FEBS Lett 2000; 472: 17-21.
42. Sardi SP, Clarke J, Kinnecom C, Tamsett TJ, Li L, Stanek LM, et al. CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci USA 2011; 108: 12101-6. doi: 10. 1073/pnas. 1108197108
43. Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol 2012; 11: 986-98.
44. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361: 1651-61. doi: 361/ 17/1651 [pii] 10. 1056/NEJMoa0901281
45. Svennerholm L, Hakansson G, Dreborg S. Assay of the beta-glucosidase activity with natural labelled and artificial substrates in leukocytes from homozygotes and heterozygotes with the Norrbottnian type (Type 3) of Gaucher disease. Clin Chim Acta 1980; 106: 183-93.
46. Takahashi M, Matsuda F, Margetic N, Lathrop M. Automated identification of single nucleotide polymorphisms from sequencing data. J Bioinform Comput Biol 2003; 1: 253-65.
47. Velayati A, DePaolo J, Gupta N, Choi JH, Moaven N, Westbroek W, et al. A mutation in SCARB2 is a modifier in gaucher disease. Hum Mut 2011; 32: 1232-8. doi: Doi 10. 1002/Humu. 21566
48. Woodard CM, Campos BA, Kuo SH, Nirenberg MJ, Nestor MW, Zimmer M, et al. iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease. Cell Rep 2014; 9: 1173-82. doi: DOI 10. 1016/j. celrep. 2014. 10. 023
49. Zhang XK, Elbin CS, Chuang WL, Cooper SK, Marashio CA, Beauregard C, et al. Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry. Clin Chem 2008; 54: 1725-8. doi: DOI 10. 1373/ clinchem. 2008. 104711